The European Commission (EC) has granted marketing authorization to expand the approved indication for Hympavzi (marstacimab). The expansion now covers adults and adolescents (12 years and older, weighing at least 35 kg) living with either hemophilia A or B who have developed inhibitors.
Addressing a Critical Treatment Challenge Inhibitors represent a major hurdle in hemophilia care as they neutralize traditional factor replacement therapies. Approximately 20% of hemophilia A and 3% of hemophilia B patients develop these inhibitors, leaving them vulnerable to uncontrolled bleeding, joint damage, and increased hospitalization risks.
Key Advantages of Hympavzi
-
Convenient Dosing: A once-weekly subcutaneous injection.
-
Reduced Burden: Does not require routine treatment-related laboratory monitoring.
-
Superior Protection: Offers enhanced bleed protection compared to standard on-demand treatments, significantly improving the quality of life for patients with high treatment burdens.
Global Regulatory Outlook While Hympavzi was approved by the FDA in October 2024 for patients without inhibitors, the U.S. regulatory body has recently granted Priority Review for this expanded indication. If approved, it could potentially lower the treatment age to as young as 6 years old in the United States.